# First-Episode Psychosis: Early Intervention Models

## The Importance of Early Intervention

### Duration of Untreated Psychosis (DUP)

DUP is defined as the time from onset of frank psychotic symptoms to initiation of adequate antipsychotic treatment. Average DUP in the United States: 1-3 years. Longer DUP is consistently associated with poorer outcomes: lower remission rates, more severe negative symptoms, greater functional impairment, poorer quality of life. The relationship between DUP and outcomes appears to be dose-dependent -- every additional month of untreated psychosis worsens prognosis. Reducing DUP through education and early detection programs is a major public health priority. The "critical period" hypothesis (Birchwood): the first 2-5 years after psychosis onset represent a window of greatest therapeutic opportunity.

### Prodromal Phase

The clinical high-risk (CHR) or attenuated psychosis syndrome precedes frank psychosis in many patients. Symptoms: attenuated positive symptoms (unusual perceptual experiences, suspiciousness), cognitive decline, social withdrawal, functional deterioration. Conversion rate from CHR to psychosis: approximately 20-35% over 2-3 years. Screening tools: Structured Interview for Psychosis-Risk Syndromes (SIPS), Comprehensive Assessment of At-Risk Mental States (CAARMS) Management of CHR: psychotherapy (CBT), psychosocial support, close monitoring; antipsychotic treatment is NOT recommended at the CHR stage unless conversion occurs.

## Coordinated Specialty Care (CSC) Programs

### The RAISE-ETP Model (Recovery After an Initial Schizophrenia Episode -- Early Treatment Program)

The landmark NIMH-funded study that established the CSC model in the United States. **NAVIGATE program:** comprehensive team-based intervention including: **Individualized medication management:** low-dose antipsychotic prescribing with shared decision-making. **Family psychoeducation:** FAMILY (Family-Aided Assertive Community Treatment) or similar models. **Individual resiliency training (IRT):** CBT-based psychotherapy. **Supported employment and education (SEE):** helping patients maintain work or school. Results: RAISE-ETP showed significantly better quality of life, symptom improvement, and functional outcomes compared to usual care at 2 years. Led to SAMHSA's Community Mental Health Block Grant set-aside for first-episode psychosis programs (10% of state mental health funds) Examples of CSC programs: OnTrackNY, NAVIGATE, EASA (Early Assessment and Support Alliance)

### Key Components of CSC

**Low-dose antipsychotic treatment:** start low, go slow; minimize side effects that drive non-adherence. **Individual therapy:** CBT for psychosis (CBTp) or similar evidence-based approach. **Family involvement:** psychoeducation, communication training, problem-solving skills. **Supported employment/education:** evidence-based vocational rehabilitation (Individual Placement and Support model) **Case management:** coordination of care, housing support, crisis intervention. **Peer support:** integration of individuals with lived experience of psychosis. **Substance use treatment:** integrated dual-disorder treatment.

## Pharmacotherapy in First-Episode Psychosis

### Low-Dose Antipsychotic Initiation

First-episode patients are more sensitive to both therapeutic effects and side effects of antipsychotics. Start at 50% of the dose typically used for chronic schizophrenia. Second-generation antipsychotics (SGAs) preferred as first-line due to lower EPS risk:

| Agent | FEP Dose Range | Chronic Schizophrenia Dose | Metabolic Risk | Key Advantages |
|-------|---------------|---------------------------|----------------|----------------|
| Aripiprazole | 5-15 mg/day | 10-30 mg/day | Low | Lowest metabolic risk; partial D2 agonism |
| Risperidone | 1-3 mg/day | 2-6 mg/day | Moderate | Well-studied; LAI available |
| Paliperidone | 3-6 mg/day | 6-12 mg/day | Moderate | No hepatic metabolism; LAI options |
| Quetiapine | 300-500 mg/day | 400-800 mg/day | Moderate-High | Sedating (useful for insomnia); low EPS |
| Olanzapine | Avoid as first-line | 10-20 mg/day | **High** | Effective but metabolic risk limits use in FEP |

Avoid olanzapine as first-line in first-episode due to high metabolic risk (weight gain, diabetes) Clozapine should be considered after failure of two adequate antipsychotic trials.

### Response and Duration of Treatment

~70-80% of first-episode patients respond to antipsychotic treatment (much higher than chronic schizophrenia) Time to response: typically 2-4 weeks, but may take up to 6-8 weeks. Duration of antipsychotic treatment after first episode is debated: Guidelines generally recommend at least 1-2 years of maintenance treatment. Relapse rates after discontinuation are high (~80% within 1-2 years vs. ~20-30% with continued treatment) Some patients (10-20%) may maintain remission after supervised, gradual discontinuation. Long-acting injectable antipsychotics are increasingly advocated in first-episode psychosis to prevent covert non-adherence and relapse.

### Metabolic Monitoring

Baseline and ongoing monitoring essential: weight, BMI, waist circumference, fasting glucose, HbA1c, lipid panel, blood pressure. Monitor at baseline, 1 month, 3 months, then every 6-12 months. Lifestyle interventions (diet, exercise) should be started concurrently with antipsychotic initiation. Switch antipsychotic if significant metabolic adverse effects develop.

## Family Psychoeducation

### Rationale

Families are essential partners in recovery. Expressed emotion (EE) -- critical comments, hostility, emotional over-involvement -- is associated with higher relapse rates. Family psychoeducation reduces relapse rates by 50% compared to standard care. Key components: illness education, communication skills training, problem-solving, crisis management, emotional support for family members. Models: McFarlane's multifamily group psychoeducation, Falloon's behavioral family therapy.

## Supported Employment and Education

### Individual Placement and Support (IPS)

Evidence-based model of supported employment for serious mental illness. Core principles: rapid job search (no "train then place"), competitive employment, integration with mental health treatment, attention to patient preferences, ongoing support. Consistently shows 2-3x higher employment rates compared to traditional vocational rehabilitation. Early application in first-episode psychosis helps patients maintain their developmental trajectory (school, career)

<image>
A diagram of the Coordinated Specialty Care (CSC) team model for first-episode psychosis. Show a central hub with the patient at the center, surrounded by spokes connecting to each team component: prescriber (low-dose medication management), individual therapist (CBTp/IRT), family therapist (psychoeducation), supported employment/education specialist, case manager, and peer support specialist. Include arrows showing bidirectional communication between team members. Label each spoke with the specific evidence-based intervention. Include outcomes data from the RAISE-ETP trial. Clean organizational diagram.
</image>

<image>
A timeline showing the progression from prodromal phase to first-episode psychosis and the impact of duration of untreated psychosis (DUP). Show a horizontal timeline with markers for: premorbid functioning, prodromal symptoms (attenuated positive symptoms, functional decline), onset of frank psychosis (threshold crossing), DUP period, and treatment initiation. Below the timeline, show outcome curves: shorter DUP leads to better trajectory, longer DUP leads to worse trajectory. Include the "critical period" window (first 2-5 years). Annotate with evidence for DUP-outcome relationship.
</image>

<image>
A dosing comparison chart for antipsychotics in first-episode vs. chronic schizophrenia. Show the recommended dose ranges for aripiprazole, risperidone, paliperidone, quetiapine, and olanzapine in first-episode patients (lower range) vs. chronic patients (standard range). Use horizontal bars with the first-episode range highlighted and the full standard range shown for comparison. Include metabolic risk ratings and EPS risk ratings for each agent. Clean clinical reference format.
</image>

## Clinical Pearls

First-episode psychosis patients respond to much lower doses of antipsychotics than chronic patients -- starting at standard chronic schizophrenia doses causes unnecessary side effects and drives non-adherence. Reducing the duration of untreated psychosis is one of the most important modifiable factors in long-term prognosis -- every month of delay matters. Coordinated specialty care programs produce superior outcomes to treatment-as-usual and are now funded in every US state through SAMHSA block grants. Family psychoeducation reduces relapse by ~50% and is among the most potent interventions in psychosis care -- yet it is consistently underutilized. Metabolic monitoring must begin at the moment of antipsychotic initiation, not after problems develop -- young patients are at particular risk for metabolic syndrome. Do not diagnose schizophrenia at first episode -- use "first-episode psychosis" or "schizophreniform disorder" until the 6-month criterion is met. Consider long-acting injectable antipsychotics early in treatment (not just after repeated relapses) -- preventing the first relapse may be more important than treating subsequent ones.

## References

- Kane JM, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. *Am J Psychiatry*. 2016;173(4):362-372.
- Correll CU, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry*. 2018;75(6):555-565.
- Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia. *Am J Psychiatry*. 2005;162(10):1785-1804.
- Dixon LB, et al. Implementing coordinated specialty care for early psychosis: the RAISE Connection Program. *Psychiatr Serv*. 2015;66(7):691-698.
- McGorry PD, et al. Early intervention in psychosis: concepts, evidence, and future directions. *World Psychiatry*. 2008;7(3):148-156.